Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 8/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.42 |
| ▸ | BCHE | P06276 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4101924 | 0.88 | SLC6A4 (0.45) | CHRM2L3MBTL1SLC2A1SLC6A4 | |
| SCHEMBL17757711 | 0.83 | SLC2A1 (0.59) | CHRM2SLC2A1GRIN1GRIN2ABCHE | |
| SCHEMBL14823439 | 0.81 | CHRM2 (0.51) | CHRM2GRIN1GRIN2A | |
| SCHEMBL15139535 | 0.78 | CHRM2 (0.49) | CHRM2SLC2A1GRIN1GRIN2A | |
| SCHEMBL17757708 | 0.75 | CHRM2 (0.67) | CHRM2L3MBTL1SIGMAR1MAOA | |
| SCHEMBL4109207 | 0.74 | ABCB1 (0.43) | CHRM2L3MBTL1SLC2A1 | |
| SCHEMBL6834728 | 0.74 | KDM4E (0.50) | SLC6A4 | |
| SCHEMBL5854479 | 0.73 | HTR2A (0.48) | CHRM2L3MBTL1SLC2A1SIGMAR1MAOA | |
| Hydrochloric Acid SCHEMBL17260135 | 0.73 | SMN1; SMN2 (0.55) | CHRM2SLC2A1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL15821796 | 0.73 | SMN1; SMN2 (0.55) | CHRM2SLC2A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926260-B2 | Polyamine transport selective therapeutic agents with enhanced stability | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160311756-A1 | POLYAMINE TRANSPORT SELECTIVE THERAPEUTIC AGENTS WITH ENHANCED STABILITY | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160299149-A1 | ASSAYS AND METHODS FOR CELL PROLIFERATION-TARGETED TREATMENT THERAPIES | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9346741-B2 | Polyamine transport selective therapeutic agents with enhanced stability | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311756-A1 | POLYAMINE TRANSPORT SELECTIVE THERAPEUTIC AGENTS WITH ENHANCED STABILITY | SLC7A1, SRM, SMS | CHRM2 4515/4885L3MBTL1 3527/4885SLC2A1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.